Sept 13 (Reuters) - Eli Lilly ( LLY ) said on Friday the

U.S. Food and Drug Administration approved its eczema drug for

use in adults and children above 12 years old.

The drug, branded Ebglyss, will be available in the next few

weeks, the company said.

The FDA's approval was based on three studies involving over

1,000 patients with moderate-to-severe eczema who were unable to

control their symptoms with topical medicines or other systemic

treatments, Eli Lilly ( LLY ) said.

Last year, the regulator had declined to approve the drug

due to certain findings during an inspection of a contract

manufacturer.